1.50
price up icon2.74%   0.04
after-market After Hours: 1.45 -0.05 -3.33%
loading
Unity Biotechnology Inc stock is traded at $1.50, with a volume of 78,690. It is up +2.74% in the last 24 hours and up +7.14% over the past month. Unity Biotechnology Inc designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells, and creating senolytic medicines. Its medicines target vulnerabilities unique to senescent cells to clear those cells from the human body while leaving normal cells unaffected. The firm focuses on age-associated diseases such as osteoarthritis, eye diseases, and pulmonary diseases. Its drug candidates include, UBX1325 is being developed for age-related diseases of the eye, including diabetic macular edema, or DME, UBX2089, which is a circulating hormone primarily produced in the kidneys and choroid plexus of the brain, which is being researched for multiple neurology indications, and UBX2050.
See More
Previous Close:
$1.46
Open:
$1.47
24h Volume:
78,690
Relative Volume:
2.04
Market Cap:
$25.27M
Revenue:
-
Net Income/Loss:
$-52.53M
P/E Ratio:
-0.3778
EPS:
-3.97
Net Cash Flow:
$-39.93M
1W Performance:
+2.74%
1M Performance:
+7.14%
6M Performance:
+0.00%
1Y Performance:
-18.48%
1-Day Range:
Value
$1.44
$1.53
1-Week Range:
Value
$1.44
$1.54
52-Week Range:
Value
$1.22
$2.26

Unity Biotechnology Inc Stock (UBX) Company Profile

Name
Name
Unity Biotechnology Inc
Name
Phone
(650) 416-1192
Name
Address
285 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA
Name
Employee
19
Name
Twitter
@unitybiotech
Name
Next Earnings Date
2024-11-11
Name
Latest SEC Filings
Name
UBX's Discussions on Twitter

Unity Biotechnology Inc Stock (UBX) Upgrades & Downgrades

Date Action Analyst Rating Change
Jan-04-22 Upgrade ROTH Capital Neutral → Buy
Nov-10-21 Upgrade Mizuho Neutral → Buy
Jun-28-21 Upgrade Citigroup Sell → Buy
Jun-07-21 Initiated H.C. Wainwright Buy
Feb-16-21 Downgrade Citigroup Neutral → Sell
Aug-18-20 Downgrade Citigroup Buy → Neutral
Aug-18-20 Downgrade Mizuho Buy → Neutral
Aug-18-20 Downgrade Morgan Stanley Overweight → Equal-Weight
Aug-17-20 Downgrade ROTH Capital Buy → Neutral
Jul-28-20 Initiated ROTH Capital Buy
Dec-12-19 Initiated Cantor Fitzgerald Overweight
Mar-07-19 Initiated Cantor Fitzgerald Overweight
Sep-07-18 Initiated Mizuho Buy
May-29-18 Initiated Citigroup Buy
May-29-18 Initiated Goldman Neutral
May-29-18 Initiated Morgan Stanley Overweight
View All

Unity Biotechnology Inc Stock (UBX) Latest News

pulisher
Oct 09, 2024

Empery Asset Management, LP Acquires Shares in Volcon Inc - Yahoo Finance UK

Oct 09, 2024
pulisher
Oct 09, 2024

Empery Asset Management's Strategic Acquisition in Elevation Oncology - Yahoo Finance

Oct 09, 2024
pulisher
Oct 09, 2024

Empery Asset Management's Strategic Reduction in Sharps Technology Inc - Yahoo Finance

Oct 09, 2024
pulisher
Sep 24, 2024

UNITY Biotechnology to Host In-Person Ophthalmology Day in New York on Tuesday, October 15, 2024 - GlobeNewswire

Sep 24, 2024
pulisher
Sep 24, 2024

UNITY Biotechnology to Host In-Person Ophthalmology Day in New York on Tuesday, October 15, 2024 - Yahoo Finance

Sep 24, 2024
pulisher
Sep 24, 2024

UNITY Biotechnology to Host In-Person Ophthalmology Day in New York on Tuesday, October 15, 2024 - StockTitan

Sep 24, 2024
pulisher
Sep 24, 2024

Unity Biotechnology (FRA:9U90) Cash Ratio : 3.85 (As of Jun. 2024) - GuruFocus.com

Sep 24, 2024
pulisher
Sep 23, 2024

Jefferies Financial Group Boosts United Therapeutics (NASDAQ:UTHR) Price Target to $432.00 - Defense World

Sep 23, 2024
pulisher
Sep 23, 2024

Tri Locum Partners LP Makes New Investment in United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat

Sep 23, 2024
pulisher
Sep 22, 2024

Epoch Investment Partners Inc. Increases Stake in United Therapeutics Co. (NASDAQ:UTHR) - Defense World

Sep 22, 2024
pulisher
Sep 22, 2024

United Therapeutics Co. (NASDAQ:UTHR) Shares Acquired by Mercer Global Advisors Inc. ADV - Defense World

Sep 22, 2024
pulisher
Sep 22, 2024

Symmetry Investments LP Makes New Investment in United Therapeutics Co. (NASDAQ:UTHR) - Defense World

Sep 22, 2024
pulisher
Sep 22, 2024

American Century Companies Inc. Has $13.14 Million Position in United Therapeutics Co. (NASDAQ:UTHR) - Defense World

Sep 22, 2024
pulisher
Sep 21, 2024

Pacer Advisors Inc. Grows Holdings in United Therapeutics Co. (NASDAQ:UTHR) - Defense World

Sep 21, 2024
pulisher
Sep 21, 2024

Meiji Yasuda Asset Management Co Ltd. Buys 33 Shares of United Therapeutics Co. (NASDAQ:UTHR) - Defense World

Sep 21, 2024
pulisher
Sep 19, 2024

Inspire Investing LLC Acquires 2,936 Shares of United Therapeutics Co. (NASDAQ:UTHR) - Defense World

Sep 19, 2024
pulisher
Sep 18, 2024

Uniti Group Inc [UNIT] stock was sold by Mudry Ronald J. at the price of US$0.11 million - Knox Daily

Sep 18, 2024
pulisher
Sep 18, 2024

1,054 Shares in United Therapeutics Co. (NASDAQ:UTHR) Bought by Choreo LLC - Defense World

Sep 18, 2024
pulisher
Sep 18, 2024

Quest Partners LLC Has $89,000 Stock Holdings in United Therapeutics Co. (NASDAQ:UTHR) - Defense World

Sep 18, 2024
pulisher
Sep 17, 2024

Liquidia Corp faces renewed legal challenge from United Therapeutics By Investing.com - Investing.com Australia

Sep 17, 2024
pulisher
Sep 17, 2024

Meeder Advisory Services Inc. Invests $36,000 in Uniti Group Inc. (NASDAQ:UNIT) - Defense World

Sep 17, 2024
pulisher
Sep 17, 2024

Unity Software Inc. (NYSE:U) Shares Bought by Daiwa Securities Group Inc. - Defense World

Sep 17, 2024
pulisher
Sep 17, 2024

Commonwealth Equity Services LLC Has $1.16 Million Position in Unity Software Inc. (NYSE:U) - Defense World

Sep 17, 2024
pulisher
Sep 16, 2024

Court rules against United Therapeutics in Liquidia case - Investing.com India

Sep 16, 2024
pulisher
Sep 15, 2024

Royal London Asset Management Ltd. Boosts Stake in Unity Software Inc. (NYSE:U) - Defense World

Sep 15, 2024
pulisher
Sep 14, 2024

694 Shares in United Therapeutics Co. (NASDAQ:UTHR) Purchased by Caprock Group LLC - Defense World

Sep 14, 2024
pulisher
Sep 04, 2024

Anti-Senescence Therapy Market is Likely to Upsurge at USD 25.16 Bn- Unity Biotechnology, OisinBiotechnologies, AgeX Therapeutics, Siwa – Daily News Mirror - Daily News Mirror

Sep 04, 2024
pulisher
Aug 31, 2024

The Top 8 Things to Know About Anti-Aging Research Right Now - upworthyscience.com

Aug 31, 2024
pulisher
Aug 20, 2024

UBX (Unity Biotechnology) Debt-to-Equity : 1.10 (As of Jun. 2024) - GuruFocus.com

Aug 20, 2024
pulisher
Aug 19, 2024

Billionaires are spending big so they — and maybe you — can live forever - MarketWatch

Aug 19, 2024
pulisher
Aug 18, 2024

Unity Biotechnology (FRA:9U90) Net-Net Working Capital : €0.01 (As of Jun. 2024) - GuruFocus.com

Aug 18, 2024
pulisher
Aug 18, 2024

UBX (Unity Biotechnology) EV-to-Revenue : (As of Aug. 18, 2024) - GuruFocus.com

Aug 18, 2024
pulisher
Aug 17, 2024

UBX (Unity Biotechnology) EPS (Basic) : $-1.74 (TTM As of Jun. 2024) - GuruFocus.com

Aug 17, 2024
pulisher
Aug 17, 2024

UBX (Unity Biotechnology) COGS-to-Revenue : 0.00 (As of Jun. 2024) - GuruFocus.com

Aug 17, 2024
pulisher
Aug 17, 2024

UBX (Unity Biotechnology) Growth Rank : 0 (As of Aug. 17, 2024) - GuruFocus.com

Aug 17, 2024
pulisher
Aug 17, 2024

UBX (Unity Biotechnology) Short-Term Debt & Capital Lease O - GuruFocus.com

Aug 17, 2024
pulisher
Aug 17, 2024

UBX (Unity Biotechnology) Purchase Of Investment : $-28.03 Mil (TTM As of Jun. 2024) - GuruFocus.com

Aug 17, 2024
pulisher
Aug 17, 2024

UBX (Unity Biotechnology) Intrinsic Value: Projected FCF : $-30.17 (As of Aug. 17, 2024) - GuruFocus.com

Aug 17, 2024
pulisher
Aug 17, 2024

Unity Biotechnology (FRA:9U90) Cash From Discontinued Inves - GuruFocus.com

Aug 17, 2024
pulisher
Aug 16, 2024

UBX (Unity Biotechnology) GF Value : $0.00 (As of Aug. 16, 2024) - GuruFocus.com

Aug 16, 2024
pulisher
Aug 12, 2024

UNITY Biotechnology to Participate in Upcoming Investor Conferences - GlobeNewswire

Aug 12, 2024
pulisher
Aug 12, 2024

UNITY Biotechnology to Participate in Upcoming Investor Conferences - StockTitan

Aug 12, 2024
pulisher
Aug 09, 2024

UNITY Biotechnology (UBX) Upgraded to Buy: Here's What You Should Know - Yahoo Finance

Aug 09, 2024
pulisher
Aug 09, 2024

Unity Biotechnology, Inc. Expected to Post Q3 2024 Earnings of ($0.40) Per Share (NASDAQ:UBX) - Defense World

Aug 09, 2024
pulisher
Aug 09, 2024

Unity Biotechnology (NASDAQ:UBX) Posts Earnings Results - Defense World

Aug 09, 2024
pulisher
Aug 09, 2024

FY2028 EPS Estimates for Unity Biotechnology, Inc. (NASDAQ:UBX) Boosted by Analyst - Defense World

Aug 09, 2024
pulisher
Aug 08, 2024

Unity Biotechnology (NASDAQ:UBX) Rating Reiterated by HC Wainwright - Defense World

Aug 08, 2024
pulisher
Aug 06, 2024

UNITY Biotechnology, Inc. Reports Second Quarter 2024 Financial Results and Business Updates - GlobeNewswire

Aug 06, 2024
pulisher
Aug 06, 2024

UNITY Biotechnology, Inc. Reports Second Quarter 2024 Financial Results and Business Updates - StockTitan

Aug 06, 2024
pulisher
Jul 24, 2024

UNITY Biotechnology Reports Granting of New Employment Inducement Award - GlobeNewswire

Jul 24, 2024
pulisher
Jul 24, 2024

UNITY Biotechnology Reports Granting of New Employment Inducement Award - StockTitan

Jul 24, 2024

Unity Biotechnology Inc Stock (UBX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Unity Biotechnology Inc Stock (UBX) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Ghosh Anirvan
Chief Executive Officer
Aug 02 '24
Sale
1.53
604
924
76,325
Sullivan Lynne Marie
CFO & Head of Corp. Dev.
Aug 02 '24
Sale
1.53
139
213
56,061
Nguyen Alexander Hieu
Chief Legal Officer
Jun 25 '24
Sale
1.40
78
109
25,026
Ghosh Anirvan
Chief Executive Officer
Jun 25 '24
Sale
1.40
1,214
1,700
76,929
Sullivan Lynne Marie
CFO & Head of Corp. Dev.
Jun 25 '24
Sale
1.40
324
454
32,685
Ghosh Anirvan
Chief Executive Officer
May 02 '24
Sale
1.55
603
935
78,143
Ghosh Anirvan
Chief Executive Officer
Feb 02 '24
Sale
1.71
680
1,163
78,746
Ghosh Anirvan
Chief Executive Officer
Jan 30 '24
Sale
1.71
1,183
2,023
79,426
Ghosh Anirvan
Chief Executive Officer
Nov 02 '23
Sale
1.83
589
1,078
80,609
Ghosh Anirvan
Chief Executive Officer
Oct 30 '23
Sale
1.90
1,024
1,946
81,198
$23.53
price down icon 0.76%
$358.22
price up icon 1.10%
$58.29
price up icon 2.57%
$236.10
price down icon 1.37%
$120.52
price up icon 1.82%
$536.70
price up icon 1.79%
Cap:     |  Volume (24h):